Abstract
Lipid metabolism disorder with a predominance of very-low-density lipoproteins (VLDL), triglycerides (TG), and cholesterol (CS) in the blood plasma contributes to the development of atherosclerotic diseases, which to date remain the main cause of death among the population, ranking first among all causes of death in the world and claiming the lives of 4 million Earth inhabitants every year. In this regard, there is a need to search for drugs that reduce the level of cholesterol, triglycerides, and VLDL in blood plasma. Such a group of drugs is PCSK9 inhibitors. Purpose of the study: to evaluate the efficacy and safety of the new class of lipid-lowering drugs — PCSK9 inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
